Alembic Pharmaceuticals Ltd

APLLTD
Health CarePharmaceuticals
SmallcapWith a market cap of ₹14,511 cr, stock is ranked 264
Low RiskStock is 1.72x as volatile as Nifty
738.251.05 (-0.14%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹14,511 cr, stock is ranked 264
Low RiskStock is 1.72x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
26.85
PB RatioPB Ratio
2.86
Dividend YieldDiv. Yield
1.35%
Sector PESector PE
30.35
Sector PBSector PB
4.67
Sector Div YldSctr Div Yld
0.91%

Forecast & RatingsDetailed Forecast 

31%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Alembic Pharmaceuticals Limited is a pharmaceutical company engaged in developing formulations and active pharmaceutical ingredients (API).

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

See Plans

Financial TrendFinancial statements 

20192020202120223.944.615.405.360.580.831.180.54
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Press Release 
Announced OnMay 24, 2022

Alembic Pharmaceuticals Limited has informed the Exchange about press release dated 24-May-2022 titled Alembic Pharmaceuticals receives USFDA Final Approval for Pirfenidone Tablets, 267 mg and 801 mg. | Download

Alembic Pharmaceuticals Limited has informed the Exchange about press release dated 24-May-2022 titled Alembic Pharmaceuticals receives USFDA Final Approval for Pirfenidone Tablets, 267 mg and 801 mg. | Download

Newspaper Advertisements 
Announced OnMay 23, 2022

Alembic Pharmaceuticals Limited has informed the Exchange about Newspaper Advertisements | Download

Alembic Pharmaceuticals Limited has informed the Exchange about Newspaper Advertisements | Download

Cash Dividend 
Ex. DateJul 19, 2021

Final • Div/Share: ₹ 14

See all events